Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74,75,76].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Young, cognitively normal apoE4 carriers have glucose hypometabolism in brain regions affected by AD [29–31]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies looking at both young and old non-demented carriers of the apoE4 isoform observed a similar regional pattern of hypometabolism prior to the onset of disease that correlates with the changes seen in the AD brain.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Small et al., 2000
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Spatial registration and normalization of images
Friston, K. J., Ashburner, J., Frith, C. D., Poline, J. ‐., Heather, J. D., & Frackowiak, R. S. J. (1995) · Human Brain Mapping · doi:10.1002/hbm.460030303 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationPopulation-Based Norms for the Mini-Mental State Examination by Age and Educational Level
Crum, R. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500180078038 · Cited by 2,929
Research works printed but not linked: 3
- Rogers, S. L. & Friedhoff, L. T. (1996) Dementia 7, 293-303.
- Huang, S. C., Phelps, M. E., Hoffman, E. J., Sideris, K., Selin, C. J. & Kuhl, D. E. (1980) Am. J. Physiol. 238, E69-82.
- Benton, A. L. (1974) The Revised Visual Retention Test (Psychological Corp., New York).
Cited by
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationRETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2005) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,687
“Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Aβ(1-42) injections in the rat.”
BackgroundThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
Distinct patterns of brain activity in young carriers of the APOE -ε4 allele
Filippini, N., MacIntosh, B. J., Hough, M. G., Goodwin, G. M., Frisoni, G. B., Smith, S. M., Matthews, P. M., Beckmann, C. F., & Mackay, C. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811879106 · Cited by 1,613
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
“[73] Small GW, Ercoli LM, Silverman DH, et al.”
Dynamics of Gray Matter Loss in Alzheimer's Disease
Thompson, P. M., Hayashi, K. M., de Zubicaray, G., Janke, A. L., Rose, S. E., Semple, J., Herman, D., Hong, M. S., Dittmer, S. S., Doddrell, D. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00994.2003 · Cited by 1,132
“, ApoE4 carriers) (Small et al., 2000; Reiman et al., 2001; see also Thompson et al., 2003).”
BackgroundGene-environment interplay and psychopathology: multiple varieties but real effects
Rutter, M., Moffitt, T. E., & Caspi, A. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2005.01557.x · Cited by 1,058
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
“Our work may provide an explanation for the observation that subtle brain dysfunction can be detected in certain individuals who are genetically at risk for AD but remain neurologically stable for many years before the expected onset of disease (Bookheimer et al. 2000; Small et al. 2000).”
BackgroundFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Self-citationAge-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease
Bartzokis, G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.03.001 · Cited by 968
“Imaging biomarkers could be used to identify individuals at high risk for developing cognitive impairments, and prospectively track the effects of treatment interventions aimed at preventing the progression of cognitive impairments in populations that have minimal symptoms or are entirely asymptomatic [10,210,215].”
BackgroundSilverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) · JAMA · doi:10.1001/jama.286.17.2120 · Cited by 951
“The P1, P2, P3, and N1, N2, N3 designations refer to the patterns illustrated in the Figure, with the “+” sign indicating the presence of abnormal findings other than parietal/ temporal/frontal hypometabolism, which would be uncharacteristic of AD.”
ResultInfluentialSelf-citationMosconi, L. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1762-7 · Cited by 898
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600549103 · Cited by 912
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
“FDG hypometabolism is also predictive of the rate of memory decline in APOE 14 carriers with mild memory loss over 2 years (Small et al. 2000).”
BackgroundDiscrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Herholz, K., Salmon, E., Perani, D., Baron, J.-C., Holthoff, V., Frölich, L., Schönknecht, P., Ito, K., Mielke, R., & Kalbe, E. (2002) · NeuroImage · doi:10.1006/nimg.2002.1208 · Cited by 832
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827
“Education†, y 13 (8, 20) 14 (8, 20) 12 (8, 20) 13 (7, 18) 13 (8, 18) 13 (8, 18)”
Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., Read, S., Satyamurthy, N., Petric, A., Huang, S.-C., et al. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00004 · Cited by 770
Self-citationScahill, R. I., Schott, J. M., Stevens, J. M., Rossor, M. N., & Fox, N. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052587399 · Cited by 764
Brain metabolism in health, aging, and neurodegeneration
Camandola, S., & Mattson, M. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695810 · Cited by 752
“Functional neuroimaging studies have shown that glucose hypometabolism and mitochondrial dysfunction are early indicators of age-related functional changes during normal brain aging (De Leon et al, 1983; Small et al, 2000: Mosconi et al, 2008).”
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI
Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., & Jagust, W. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.07.002 · Cited by 750
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054625 · Cited by 738
Self-citationIn Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease
Baron, J. C., Chételat, G., Desgranges, B., Perchey, G., Landeau, B., de la Sayette, V., & Eustache, F. (2001) · NeuroImage · doi:10.1006/nimg.2001.0848 · Cited by 684
Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications
Brann, D. W., Dhandapani, K., Wakade, C., Mahesh, V. B., & Khan, M. M. (2007) · Steroids · doi:10.1016/j.steroids.2007.02.003 · Cited by 647
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
“For example, decreases in brain metabolism are seen many years before the development of symptoms in patients predisposed to AD (Small et al., 2000), and this may reflect a very early dysfunction in by guest on O ctober 7, 2016 http://ijnp.oxfordjournals.org/ D ow nloaded from synaptic connectivity.”
Backgroundde Leon, M. J., Convit, A., Wolf, O. T., Tarshish, C. Y., DeSanti, S., Rusinek, H., Tsui, W., Kandil, E., Scherer, A. J., Roche, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191044198 · Cited by 629
Siebner, H., Riemenschneider, M., Willoch, F., Minoshima, S., Schwaiger, M., Kurz, A., Drzezga, A., & Lautenschlager, N. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1194-1 · Cited by 603
Functional Alterations in Memory Networks in Early Alzheimer’s Disease
Sperling, R. A., Dickerson, B. C., Pihlajamaki, M., Vannini, P., LaViolette, P. S., Vitolo, O. V., Hedden, T., Becker, J. A., Rentz, D. M., Selkoe, D. J., et al. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8109-7 · Cited by 604
“…activity is due to alterations in baseline synaptic activity, as these regions typically demonstrate hypometabolism at rest in AD patients (Meltzer et al. 1996; Silverman et al. 2001; Alexander et al. 2002) and subjects at-risk for AD (Small et al. 2000; Reiman et al. 2004; Jagust et al. 2006).”
BackgroundBrain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease
Mosconi, L., Pupi, A., & De Leon, M. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.007 · Cited by 595
ApoE genotype accounts for the vast majority of AD risk and AD pathology
Raber, J., Huang, Y., & Ashford, J. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.023 · Cited by 599
“In addition, in cognitively non-demented individuals, those withε4 show reduced brain metabolism and increased brain activation during recall [53].”
BackgroundLiang, W. S., Reiman, E. M., Valla, J., Dunckley, T., Beach, T. G., Grover, A., Niedzielko, T. L., Schneider, L. E., Mastroeni, D., Caselli, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709259105 · Cited by 585
He, Y., Wang, L., Zang, Y., Tian, L., Zhang, X., Li, K., & Jiang, T. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.11.042 · Cited by 530
“Many PET studies have consistently shown reduced resting metabolism in the PCC/ PCu in subjects with AD (Buckner et al., 2005; Leon et al., 2001; Salmon et al., 2000; Volkow et al., 2002) or cognitively intact subjects with genetic susceptibility to AD (Reiman et al., 1996; Small et al., 2000).”
BackgroundThe Alzheimer's Disease Neuroimaging Initiative positron emission tomography core
Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., Price, J. C., Reiman, E. M., Skovronsky, D., Koeppe, R. A., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.003 · Cited by 533
“In comparison with APOE 34 noncarriers in the same subject group, APOE 34 carriers in the NC group had significantly lower CMRgl in several AD-affected regions, supporting previous findings from this group [6,7] and others [8,9].”
ResultAlexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I., & Reiman, E. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.738 · Cited by 532
“Using functional neuroimaging to detect in vivo longitudinal changes in glucose metabolism directly in the brain may greatly enhance the ability to evaluate longterm treatments in the earliest stages of Alzheimer’s disease ( 14 , 15).”
BackgroundChételat, G., Landeau, B., Eustache, F., Mézenge, F., Viader, F., de la Sayette, V., Desgranges, B., & Baron, J.-C. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.05.015 · Cited by 526
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases
Jensen, N. J., Wodschow, H. Z., Nilsson, M., & Rungby, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228767 · Cited by 446
“Especially in AD, the glucose consumption monitored by 18F-FDG PET uptake correlates closely with cognitive performance and may be used as part of the diagnostic procedure [65].”
MethodPET imaging of amyloid in Alzheimer's disease
Nordberg, A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00853-1 · Cited by 464
Reiman, E. M., Caselli, R. J., Chen, K., Alexander, G. E., Bandy, D., & Frost, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061509598 · Cited by 467
fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease
Sperling, R. A. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.1.44 · Cited by 451
Willhite, C. C., Karyakina, N. A., Yokel, R. A., Yenugadhati, N., Wisniewski, T. M., Arnold, I. M. F., Momoli, F., & Krewski, D. (2014) · Critical Reviews in Toxicology · doi:10.3109/10408444.2014.934439 · Cited by 412
“…for the suggestion that metabolic acidosis (Yates et al. 1990) associated with inflammation (Akiyama et al. 2000), impaired energy metabolism (Small et al. 2000) or increased oxidative stress coupled with the actions of ionized metals might contribute to the pathogenesis of AD and/or other…”
BackgroundLandmark-based deep multi-instance learning for brain disease diagnosis
Liu, M., Zhang, J., Adeli, E., & Shen, D. (2018) · Medical Image Analysis · doi:10.1016/j.media.2017.10.005 · Cited by 425
Brain amyloid-β oligomers in ageing and Alzheimer’s disease
Lesné, S. E., Sherman, M. A., Grant, M., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Ashe, K. H. (2013) · Brain · doi:10.1093/brain/awt062 · Cited by 409
Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment
Nestor, P. J., Fryer, T. D., Smielewski, P., & Hodges, J. R. (2003) · Annals of Neurology · doi:10.1002/ana.10669 · Cited by 412
The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis
Wisdom, N. M., Callahan, J. L., & Hawkins, K. A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.003 · Cited by 415
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Petrella, J. R., Coleman, R. E., & Doraiswamy, P. M. (2003) · Radiology · doi:10.1148/radiol.2262011600 · Cited by 427
“Studies in which “at-risk” populations were examined have shown mixed results with increased (117) or decreased (123,124) activation in the at-risk group, as compared with activation in a control group.”
Aging and Spatial Navigation: What Do We Know and Where Do We Go?
Moffat, S. D. (2009) · Neuropsychology Review · doi:10.1007/s11065-009-9120-3 · Cited by 364
“Sjolinder et al. (2005) administered a virtual navigation task to a sample of young and older participants and replicated the basic findings of impaired performance in older participants and impaired configural representation of the environment.”
BackgroundResultHinrichs, C., Singh, V., Xu, G., & Johnson, S. C. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.081 · Cited by 405
“, 1994) can be identified (in structural and functional images) in Mild Cognitive Impaired (MCI) and AD subjects, as well as at-risk individuals (Small et al., 2000; Querbes et al., 2009; Davatzikos et al., 2009).”
BackgroundGood, C. D., Scahill, R. I., Fox, N. C., Ashburner, J., Friston, K. J., Chan, D., Crum, W. R., Rossor, M. N., & Frackowiak, R. S. J. (2002) · NeuroImage · doi:10.1006/nimg.2002.1202 · Cited by 410
Probing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500579102 · Cited by 401
Self-citationPGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia
Qin, W., Haroutunian, V., Katsel, P., Cardozo, C. P., Ho, L., Buxbaum, J. D., & Pasinetti, G. M. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.588 · Cited by 378
Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease
Korte, N., Nortley, R., & Attwell, D. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02215-w · Cited by 350
Functional connectivity hubs in the human brain
Tomasi, D., & Volkow, N. D. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.05.024 · Cited by 367
“The females higher connectivity in DMN regions, which show metabolic decrements in Alzheimer’s disease (AD) (Small et al., 2000), could help explain why female AD-patients show greater impairments than male patients for the equivalent reduction in cerebral metabolic rate (Perneczky et al.”
Liang, W. S., Dunckley, T., Beach, T. G., Grover, A., Mastroeni, D., Walker, D. G., Caselli, R. J., Kukull, W. A., McKeel, D., Morris, J. C., et al. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00208.2006 · Cited by 342
“AD (2, 3, 6, 7, 8, 9, 17, 18, 21, 25, 26, 27, 30, 31, 32, 47, 50, 54, 58, 63 ).”
MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET
Mosconi, L., Perani, D., Sorbi, S., Herholz, K., Nacmias, B., Holthoff, V., Salmon, E., Baron, J.-C., De Cristofaro, M. T. R., Padovani, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147469.18313.3b · Cited by 343
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F., & Tariot, P. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0059 · Cited by 339
“Brain imaging and other biomarker methods continue to be further developed and used to detect and track changes associated with the clinical progression of AD, and several of these methods have been used to detect and track similar changes in the presymptomatic stages of AD [19–34].”
Ketone Bodies as a Therapeutic for Alzheimer's Disease
Henderson, S. T. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.004 · Cited by 323
“In a series of experiments, Reiman et al. 15 examined the onset of hypometabolism in nondemented subjects at risk for AD.”
MethodInfluentialGENETICS OF BRAIN STRUCTURE AND INTELLIGENCE
Toga, A. W., & Thompson, P. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135655 · Cited by 315
“Because neuroprotective drugs are effective in early dementia (Lehtovirta et al. 1995, 2000; Small et al. 2000) there is interest in associating patterns of brain change with specific genetic markers, especially if these patterns predict imminent disease onset among individuals at genetic risk.”
BackgroundChang, S., Ma, T. R., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508254102 · Cited by 319
Liu, M., Zhang, J., Adeli, E., & Shen, D. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2018.2869989 · Cited by 308
“However, the hypothesis on ROIs requires expert knowledge in defining disease-related abnormal regions of a brain [32].”
Early Diagnosis of Alzheimer's Disease: Clinical and Economic Benefits
Leifer, B. P. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.5153.x · Cited by 297
Liang, W. S., Dunckley, T., Beach, T. G., Grover, A., Mastroeni, D., Ramsey, K., Caselli, R. J., Kukull, W. A., McKeel, D., Morris, J. C., et al. (2008) · Physiological Genomics · doi:10.1152/physiolgenomics.00242.2007 · Cited by 309
Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease
Watson, G. S., & Craft, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.048 · Cited by 307
Achieving and Maintaining Cognitive Vitality With Aging
Fillit, H. M., Butler, R. N., O'Connell, A. W., Albert, M. S., Birren, J. E., Cotman, C. W., Greenough, W. T., Gold, P. E., Kramer, A. F., Kuller, L. H., et al. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.7.681 · Cited by 300
Arnáiz, E., Jelic, V., Almkvist, O., Wahlund, L.-O., Winblad, B., Valind, S., & Nordberg, A. (2001) · Neuroreport · doi:10.1097/00001756-200103260-00045 · Cited by 302
Age differences in the neural systems supporting human allocentric spatial navigation
Moffat, S. D., Elkins, W., & Resnick, S. M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.05.011 · Cited by 270
Alzheimer Disease: Evaluation of a Functional MR Imaging Index as a Marker
Li, S.-J., Li, Z., Wu, G., Zhang, M.-J., Franczak, M., & Antuono, P. G. (2002) · Radiology · doi:10.1148/radiol.2251011301 · Cited by 292
Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging
Mosconi, L., Berti, V., Glodzik, L., Pupi, A., De Santi, S., & de Leon, M. J. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091504 · Cited by 277
“With respect to genetic risk factors for late-onset AD, many studies have shown that non-demented individuals carrying an apolipoprotein E (ApoE) ε4 allele have CMRglc reductions as compared to ApoE ε4 non-carriers [49-53].”
BackgroundAlzheimer's β-Amyloid Peptides Compete for Insulin Binding to the Insulin Receptor
Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., van Bronswijk, W., & Martins, R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-10-j0001.2002 · Cited by 291
“Furthermore, the major genetic risk factor for AD, the -4 allele of apolipoprotein E, is associated with lowered cerebral glucose metabolism in patients with a clinical diagnosis of AD (Small et al., 2000).”
BackgroundZhao, W.-Q., & Townsend, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.014 · Cited by 291
Positron emission tomography imaging in dementia
HERHOLZ, K., CARTER, S. F., & JONES, M. (2007) · The British Journal of Radiology · doi:10.1259/bjr/97295129 · Cited by 287
Gender differences in brain functional connectivity density
Tomasi, D., & Volkow, N. D. (2012) · Human Brain Mapping · doi:10.1002/hbm.21252 · Cited by 282
“These regions seem to be among the first to show metabolic decrements in Alzheimer’s disease (AD) [Small et al., 2000], which is believed to reflect the greater energetic requirements of these regions.”
BackgroundInsulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272
“Central metabolic dysfunction is a well-established feature of AD, evidenced by brain glucose hypometabolism that can be observed potentially decades prior to the development of AD symptoms (Reiman et al., 1996; Small et al., 2000; Sperling et al., 2011).”
BackgroundPPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
Landreth, G., Jiang, Q., Mandrekar, S., & Heneka, M. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.003 · Cited by 277
Multifunctional role of astrocytes as gatekeepers of neuronal energy supply
Stobart, J. L., & Anderson, C. M. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00038 · Cited by 264
“…metabolism is diminished in pre-clinical patients (Mosconi et al., 2008) and cerebral glucose uptake in transgenic AD mice (Merlini et al., 2011) and AD patients (Alexander et al., 2002) is significantly reduced, often before Aβ plaques or neurofibrillary tangles are detected (Small et al., 2000).”
BackgroundBetter Memory and Neural Efficiency in Young Apolipoprotein E 4 Carriers
Mondadori, C. R. A., de Quervain, D. J. F., Buchmann, A., Mustovic, H., Wollmer, M. A., Schmidt, C. F., Boesiger, P., Hock, C., Nitsch, R. M., Papassotiropoulos, A., et al. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhl103 · Cited by 267
Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease
Atamna, H., & Frey, W. H. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.06.001 · Cited by 278
Astrocyte dysfunction in Alzheimer disease
Acosta, C., Anderson, H. D., & Anderson, C. M. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24075 · Cited by 247
“There is increasing evidence that glucose hypometabolism is an early hallmark of AD (Chen and Zhong, 2013) that can occur before the appearance of amyloid plaques and NFTs (Small et al., 2000).”
BackgroundDissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment
Chetelat, G. (2003) · Brain · doi:10.1093/brain/awg196 · Cited by 264
“(Reiman et al., 1996; Small et al., 2000), and asymptomatic subjects carrying the presenilin-1 mutation (Johnson et al.”
BackgroundBokde, A. L. W., Lopez-Bayo, P., Meindl, T., Pechler, S., Born, C., Faltraco, F., Teipel, S. J., Möller, H.-J., & Hampel, H. (2006) · Brain · doi:10.1093/brain/awl051 · Cited by 260
“, 2004) or on differences in activation due to a cognitive paradigm measured using PET or functional MRI (fMRI) (Pietrini et al., 1996; Backman et al., 2000; Bookheimer et al., 2000; Rombouts et al., 2000; Small et al., 2000; Grady et al., 2001, 2003; Greicius et al., 2004; Rombouts et al., 2005).”
BackgroundMethodShaw, P., Lerch, J. P., Pruessner, J. C., Taylor, K. N., Rose, A. B., Greenstein, D., Clasen, L., Evans, A., Rapoport, J. L., & Giedd, J. N. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70106-0 · Cited by 257
Velliquette, R. A., O'Connor, T., & Vassar, R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2350-05.2005 · Cited by 254
SPERLING, R. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.009 · Cited by 245
Liu, Y., Wang, K., YU, C., He, Y., Zhou, Y., Liang, M., Wang, L., & Jiang, T. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.01.027 · Cited by 248
Melnyk, S., Fuchs, G. J., Schulz, E., Lopez, M., Kahler, S. G., Fussell, J. J., Bellando, J., Pavliv, O., Rose, S., Seidel, L., et al. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1260-7 · Cited by 250
“…Metabolic Epigenetics Glutathione DNA methylation The metabolic pathology of autism is relatively unexplored even though metabolic imbalance is implicated in the pathogenesis of multiple other neurobehavioral disorders (Frankenburg 2007; Gysin et al. 2007; Small et al. 2000; Smythies et al. 1997).”
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
“The imaging literature has numerous examples of healthy older APOE4 carriers with AD-like changes in glucose metabolism (Reiman et al. 1996; Small et al. 2000, 1995).”
Cohen, A. D., Price, J. C., Weissfeld, L. A., James, J., Rosario, B. L., Bi, W., Nebes, R. D., Saxton, J. A., Snitz, B. E., Aizenstein, H. A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3669-09.2009 · Cited by 240
“Similar hypometabolism was reported in carriers of the apolipoprotein-E 4 allele, an AD risk factor (Reiman et al., 1996; Small et al., 2000).”
BackgroundValla, J., Berndt, J. D., & Gonzalez-Lima, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-13-04923.2001 · Cited by 237
“Positron emission tomography (PET) studies on subjects homozygotic for the e4 allele of the apolipoprotein E (APOE) gene, with no symptoms of AD, demonstrate metabolic reductions in posterior cingulate, parietal, temporal, and prefrontal cortices (Reiman et al., 1996; Small et al., 2000).”
BackgroundJohnson, S. C., Schmitz, T. W., Moritz, C. H., Meyerand, M. E., Rowley, H. A., Alexander, A. L., Hansen, K. W., Gleason, C. E., Carlsson, C. M., Ries, M. L., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.017 · Cited by 234
“PC hypometabolism and blood flow are frequent findings in mild AD [42] and MCI [66], and in people with genetic risk for AD [48,49,58].”
BackgroundMosconi, L., De Santi, S., Brys, M., Tsui, W. H., Pirraglia, E., Glodzik-Sobanska, L., Rich, K. E., Switalski, R., Mehta, P. D., Pratico, D., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.030 · Cited by 238
“On the other hand, we did not find CMRglc deficits in the posterior cingulate cortex (PCC) of our E4 carriers, which was found in some FDG-PET ApoE studies (3,5) but not in others (6,10).”
BackgroundMethodInfluentialMaternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism
Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., Tsui, W., De Santi, S., & de Leon, M. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705036104 · Cited by 237
Silverman, D. H. S. (2004) · PubMed · Cited by 276
Self-citationChristensen, H., Mackinnon, A. J., Korten, A., & Jorm, A. F. (2001) · Psychology and Aging · doi:10.1037//0882-7974.16.4.588 · Cited by 227
Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset
Hinrichs, C., Singh, V., Mukherjee, L., Xu, G., Chung, M. K., & Johnson, S. C. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.05.056 · Cited by 228
“, 1994) can be identified (in structural and functional images) in Mild Cognitive Impaired (MCI) and AD patients, as well as at-risk individuals (Small et al., 2000).”
Metadata
- Authors
- Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., Mazziotta, J. C., Saxena, S., Wu, H. M., Mega, M. S., Cummings, J. L., Saunders, A. M., Pericak-Vance, M. A., Roses, A. D., Barrio, J. R., & Phelps, M. E.
- Affiliations
- University of California, Los Angeles (US)
- Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024; Departments of Molecular and Medical Pharmacology and Neurology, and Brain Mapping Center, University of California, Los Angeles, CA 90095; Department of Medicine, Duke University Medical Center, Durham, NC 27710; and Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2000-05-16
- Volume
- 97
- Issue
- 11
- Pages
- 6037-6042
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC18554
- OpenAlex
- W2164303459
- Cited by
- 790
- References
- 53
- Citations by year
- 2026: 13 · 2025: 8 · 2024: 12 · 2023: 17 · 2022: 20 · 2021: 17 · 2020: 24 · 2019: 20 · 2018: 17 · 2017: 22 · 2016: 17 · 2015: 14 · 2014: 27 · 2013: 34 · 2012: 30
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Energy
- Alzheimer's Association
- Ahmanson Foundation
- National Institutes of Health (AG10123, MH52453, NS26630)
- U.S. Public Health Service
- National Institute on Aging (AG-13308, P50AG016570, P50AG005128, R01AG013308, P60AG011268, P30AG010123, U24AG021886)
- National Institute of Mental Health (MH52453, R01MH052453)
- National Institute of Neurological Disorders and Stroke (P01NS026630, R01NS031153)
- National Center for Research Resources (M01RR000865)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, APOE ε4, genetic risk, brain glucose metabolism, cognitive decline, posterior cingulate cortex, inferior parietal cortex, lateral temporal cortex, preclinical Alzheimer's disease, memory performance, non-demented elderly, longitudinal follow-up
- MeSH terms
- Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Apolipoproteins E, Brain, Cognition Disorders, Female, Follow-Up Studies, Genotype, Humans, Male, Memory Disorders, Middle Aged, Psychological Tests, Risk Factors, Tomography, Emission-Computed, Genetic Predisposition to Disease, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.